January 30, 2025 - The Independent Committee for Control of Data (IDMC) gave uniqure a "emerald light" to begin patient registration in the second group of clinical trials of phase 1-2 episod1 (nct06100276), in the process which AMT-162, a vector-based gene therapy in the likeness of the adeno-associated virus (AAV), https://TherapyStemCellFrance.com/ for the treatment of ALS caused by mutations in superoxide dismutase 1 (sod1-als), is being evaluated.